MARKET

PTCT

PTCT

Ptc Therapeutics
NASDAQ
28.20
-0.11
-0.39%
After Hours: 28.74 +0.54 +1.91% 16:19 02/28 EST
OPEN
28.18
PREV CLOSE
28.31
HIGH
28.92
LOW
27.98
VOLUME
779.99K
TURNOVER
0
52 WEEK HIGH
59.84
52 WEEK LOW
17.53
MARKET CAP
2.13B
P/E (TTM)
-3.2557
1D
5D
1M
3M
1Y
5Y
PTC Therapeutics Q4 2023 Earnings Preview
Seeking Alpha · 8h ago
Earnings Preview: PTC Therapeutics
PTC Therapeutics is set to give its latest quarterly earnings report on Thursday, 2024-02-29. Analysts estimate the company will report an earnings per share of $0.50. Last quarter the company missed its earnings estimate by $1.05. Shares of PTC Therapedutics are down 36.73% over the last 52-week period.
Benzinga · 12h ago
SHAREHOLDER ALERT: Potential Recovery for PTC Therapeutics, Inc. (PTCT) Investors
TipRanks · 1d ago
Weekly Report: what happened at PTCT last week (0219-0223)?
Weekly Report · 2d ago
Weekly Report: what happened at PTCT last week (0212-0216)?
Weekly Report · 02/19 09:02
Ptc Therapeutics: Statement of changes in beneficial ownership of securities
Press release · 02/16 23:57
Will Karyopharm Therapeutics (KPTI) Report Negative Q4 Earnings? What You Should Know
NASDAQ · 02/14 15:00
PTC Therapeutics Insiders Sell US$1.1m Of Stock, Possibly Signalling Caution
PTC Therapeutics, Inc. Insiders sold their shares over the last year. The CEO & Director Matthew Klein made the biggest insider sale in the last 12 months. There was more insider selling, than buying, of PTCTherapeutics shares in the past year. But the company does not have a high level of insider ownership. In the last three months PTC TherAPEutics insiders own 2.5% of the company. It's important to pay attention to whether insiders are buying or selling shares.
Simply Wall St · 02/14 13:18
More
About PTCT
PTC Therapeutics, Inc. is a science-driven, global biopharmaceutical company. The Company is focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. Its portfolio pipeline includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology, metabolism and oncology. The Company has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD). It also offers Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, and Evrysdi, a treatment for spinal muscular atrophy (SMA). Its splicing platform includes PTC518, which is being developed for the treatment of Huntington’s disease (HD).

Webull offers PTC Therapeutics, Inc. stock information, including NASDAQ: PTCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTCT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PTCT stock methods without spending real money on the virtual paper trading platform.